التفاصيل البيبلوغرافية
| العنوان: |
Doctor, how long? |
| المؤلفون: |
MIRANDA, V. DA COSTA, DE SOUZA FEDE, Â. B., MARTINS, F. D., DE MAGALHÃES, N. P., SCHAFFHAUSSER, H. DE LAZZARI, RIECHELMANN, R. P., GIGLIO, A. D. |
| المصدر: |
European Journal of Cancer Care; Jan2011, Vol. 20 Issue 1, p50-55, 6p, 2 Charts, 1 Graph |
| مصطلحات موضوعية: |
ANALYSIS of variance, ANESTHESIA, COMPUTER software, CONFIDENCE intervals, EPIDEMIOLOGY, MULTIVARIATE analysis, PROBABILITY theory, STATISTICS, SURVIVAL analysis (Biometry), TERMINAL care, TIME, TUMORS, DATA analysis, PROPORTIONAL hazards models, RETROSPECTIVE studies |
| مصطلحات جغرافية: |
BRAZIL |
| مستخلص: |
DA COSTA MIRANDA V., DE SOUZA FEDE Â.B., MARTINS F.D., DE MAGALHÃES N.P., DE LAZZARI SCHAFFHAUSSER H., RIECHELMANN R.P. & GIGLIO A.D. (2011) European Journal of Cancer Care, 50-55 This study aimed to quantify the average survival time of cancer patients once terminal sedation was started until death and identify potential variables that may influence their survival time on sedation. This is a retrospective cohort analysis of all consecutive terminal cancer patients who died after starting terminal sedation at public tertiary Brazilian Hospital. A total of 532 cancer patients died in Hospital Estadual Mário Covas during this period and 181 out of them who received terminal sedation were included in this analysis. The median survival was 27 h. By multivariate analysis, increase in the dose of sedative drug during sedation (odds ratio 1.576, 95% CI 1.113-2.232), use of opioids alone for sedation (odds ratio 1.438, 95% CI 1.046-1.977) and dyspnoea as cause of sedation (odds ratio 1.564 95% CI 1.045-2.341) were independent risk factors for a shorter survival time after starting terminal sedation. Sedated, terminal cancer patients usually live about 1 day. We identified risk factors for a shorter sedation period. This study is limited by its retrospective design and by the frequent use of opioids as the main sedative medications. Prospective studies must be carried out in order to validate these data. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Cancer Care is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder